1h Free Analyst Time
The CT/NG Testing Market size was estimated at USD 1.63 billion in 2023, USD 1.74 billion in 2024, and is expected to grow at a CAGR of 7.41% to reach USD 2.69 billion by 2030.The CT/NG testing is primarily focused on the accurate diagnosis, management, and prevention of sexually transmitted infections (STIs), including Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The increasing prevalence of chlamydia and gonorrhea infections worldwide and rising awareness about the risks associated with untreated STIs also fuel the need for timely identification and appropriate treatment options. Technological diagnostics advancements offer opportunities for improving accuracy in detecting CT/NG infections while minimizing turnaround times. The development of POC test kits, allowing rapid results without any need for laboratory infrastructure, has gained immense popularity since it enables faster clinical decision-making. However, high costs associated with advanced diagnostic tests coupled with variations in government regulations across different countries concerning diagnostic tests limit product penetration worldwide. Nevertheless, the growing adoption of molecular diagnostics methods and government-led initiatives to promote STI screening programs to facilitate early detection and prevention of complications associated with untreated infections contribute positively to the growth of the CT/NG testing market. Speak directly to the analyst to clarify any post sales queries you may have.
Regional Insights
A growing demand for point-of-care diagnostics for sexually transmitted infections (STIs), increasing prevalence of chlamydia and gonorrhea infections, and government initiatives targeting early detection and treatment have expanded the need for CT/NG testing. In the EU countries, a rising focus on STI prevention programs to address the public health challenges investments for improving diagnostic methods through research contribute to the CT/NG testing market. The Middle East & Africa region exhibits significant potential for CT/NG testing growth due to increased government efforts towards improving STI awareness and access to healthcare services. With a large population and growing awareness around sexual health following education campaigns by the Asia-Pacific government, the region presents a lucrative CT/NG testing market.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the CT/NG Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CT/NG Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the CT/NG Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Binx Health, Inc., Bio-Rad Laboratories, Inc., Bioneer Corporation, Danaher Corporation, ELITech Group SAS, F. Hoffmann-La Roche Ltd., Geneproof A.S., Genetic Signatures Ltd., Goffin Molecular Technologies B.V., Hologic, Inc., Meridian Bioscience Inc., Microbiologics, Inc., Molbio Diagnostics Pvt. Ltd., Operon S.A., PerkinElmer Inc., QIAGEN N.V., Sansure Biotech Inc., Seegene, Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tianlong Technology Co., Ltd., Vircell S.L., and Visby Medical, Inc.Market Segmentation & Coverage
This research report categorizes the CT/NG Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Assays & Kits
- Instruments & Analyzers
- Testing Type
- Lab Tests
- PoC Tests
- Technology
- Immunodiagnostics
- Isothermal Nucleic Acid Amplification Technology
- Polymerase Chain Reaction
- End User
- Clinical Laboratories
- Hospitals & Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the CT/NG Testing Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the CT/NG Testing Market?
- What are the technology trends and regulatory frameworks in the CT/NG Testing Market?
- What is the market share of the leading vendors in the CT/NG Testing Market?
- Which modes and strategic moves are suitable for entering the CT/NG Testing Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. CT/NG Testing Market, by Product
7. CT/NG Testing Market, by Testing Type
8. CT/NG Testing Market, by Technology
9. CT/NG Testing Market, by End User
10. Americas CT/NG Testing Market
11. Asia-Pacific CT/NG Testing Market
12. Europe, Middle East & Africa CT/NG Testing Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Becton, Dickinson and Company
- Binx Health, Inc.
- Bio-Rad Laboratories, Inc.
- Bioneer Corporation
- Danaher Corporation
- ELITech Group SAS
- F. Hoffmann-La Roche Ltd.
- Geneproof A.S.
- Genetic Signatures Ltd.
- Goffin Molecular Technologies B.V.
- Hologic, Inc.
- Meridian Bioscience Inc.
- Microbiologics, Inc.
- Molbio Diagnostics Pvt. Ltd.
- Operon S.A.
- PerkinElmer Inc.
- QIAGEN N.V.
- Sansure Biotech Inc.
- Seegene, Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Tianlong Technology Co., Ltd.
- Vircell S.L.
- Visby Medical, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 188 |
| Published | March 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.74 Billion |
| Forecasted Market Value ( USD | $ 2.69 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
